Antonio Pagliuca
A5081252933- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- Neutropenia and Cancer Infections
- Immune Cell Function and Interaction
- Antifungal resistance and susceptibility
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Fungal Infections and Studies
- CAR-T cell therapy research
- Cytomegalovirus and herpesvirus research
- Polyomavirus and related diseases
- Multiple Myeloma Research and Treatments
- T-cell and B-cell Immunology
- T-cell and Retrovirus Studies
- Viral-associated cancers and disorders
- COVID-19 and healthcare impacts
- Hematological disorders and diagnostics
- Renal Transplantation Outcomes and Treatments
- Mesenchymal stem cell research
- Hemoglobinopathies and Related Disorders
- COVID-19 Clinical Research Studies
- Blood disorders and treatments
King's College Hospital
2016-2025
King's College Hospital NHS Foundation Trust
2015-2024
King's College London
2013-2024
Anthony Nolan
2022-2023
King's College - North Carolina
1990-2022
University of Cologne
2021
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino
2021
National Health Service
2011-2021
University Hospital Cologne
2021
King's College School
1990-2019
Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life threatening complication that can develop after hematopoietic cell transplantation. Although SOS/VOD progressively resolves within few weeks in most patients, the severe forms result multi-organ dysfunction and are associated with high mortality rate (>80%). Therefore, careful attention must be paid to allow an early detection of SOS/VOD, particularly drugs have now proven effective...
The advances in hematopoietic cell transplantation (HCT) over the last decade have led to a transplant-related mortality below 15%. Hepatic sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) is life-threatening complication of HCT that belongs group diseases increasingly identified as transplant-related, systemic endothelial diseases. In most cases, SOS/VOD resolves within weeks; however, severe results multi-organ dysfunction/failure with rate >80%. A timely diagnosis critical...
Summary of Key Recommendations Diagnosis It is recommended that the diagnosis veno‐occlusive disease (sinusoidal obstruction syndrome) [VOD (SOS)] be based primarily on established clinical criteria (modified Seattle or Baltimore criteria) (1A). Ultrasound imaging may helpful in exclusion other disorders patients with suspected VOD (SOS) (1C). liver biopsy reserved for whom unclear and there a need to exclude diagnoses biopsies are undertaken using transjugular approach order reduce risks...
Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics HM patients developing COVID-19 and analyzed predictors mortality. The survey was supported by the Scientific Working Group Infection Hematology European Association (EHA). Eligible analysis were adult laboratory-confirmed...
Summary Antifungal prophylaxis for allogeneic haematopoietic stem‐cell transplant (alloHCT) recipients should prevent invasive mould and yeast infections (IFIs) be well tolerated. This prospective, randomized, open‐label, multicentre study compared the efficacy safety of voriconazole (234 patients) versus itraconazole (255 in alloHCT recipients. The primary composite endpoint, success prophylaxis, incorporated ability to tolerate drug ≥100 d (with ≤14 interruption) with survival day 180...
Summary CD19 CAR‐T have emerged as a new standard treatment for relapsed/refractory (r/r) large B‐cell lymphoma (LBCL). real‐world (RW) outcomes published to date suggest significant variability across countries. We provide results of national cohort patients intended be treated with in the UK. Consecutive r/r LBCL approved by National Clinical Panel between December 2018 and November 2020 all UK centres were included. 404/432 [292 axicabtagene ciloleucel (axi‐cel), 112 tisagenlecleucel...
Limited data are available on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Adult HM, ≥1 dose of anti-SARS-CoV-2 vaccine, and between January 2021 March 2022 were analyzed. A total 1548 cases included, mainly lymphoid malignancies (1181 cases, 76%). After viral sequencing 753 (49%), the Omicron variant was prevalent (517, 68.7%). Most received ≤2 vaccine doses before (1419, 91%), mostly...
The impact of Janus kinase (JAK) 1/2 inhibitor therapy before allogeneic hematopoietic cell transplantation (HCT) has not been studied in a large cohort myelofibrosis (MF). In this retrospective multicenter study, we analyzed outcomes patients who underwent HCT for MF with prior exposure to JAK1/2 inhibitors. One hundred consecutive from participating centers were analyzed, and based on clinical status response inhibitors at the time HCT, stratified into 5 groups: (1) improvement (n = 23),...
In a multicenter collaboration, we carried out T cell-replete, peripheral blood stem cell (PBSC) transplantations from related, HLA-haploidentical donors with reduced-intensity conditioning (RIC) and post-transplantation cyclophosphamide (Cy) as graft-versus-host disease (GVHD) prophylaxis in 55 patients high-risk hematologic disorders. Patients received 2 doses of Cy 50 mg/kg i.v. on days 3 4 after infusion PBSC (mean, 6.4 × 10(6)/kg CD34(+) cells; mean, 2.0 10(8)/kg CD3(+) cells). The...
New transplant approaches are urgently needed for patients with refractory severe aplastic anemia (SAA) who lack a matched sibling or unrelated donor (UD) have failed UD cord blood transplant. Patients SAA at risk of later clonal evolution to myelodysplastic syndrome and acute leukemia. We report our pilot findings haploidentical hematopoietic stem cell transplantation (haploHSCT) using uniform reduced-intensity conditioning postgraft high-dose cyclophosphamide in 8 rejected prior Six...
HLA matching at an allelic-level resolution for volunteer unrelated donor (VUD) hematopoietic cell transplantation (HCT) results in improved survival and fewer post-transplant complications. Limitations typing technologies used the hyperpolymorphic genes have meant that variations outside of antigen recognition domain (ARD) not been previously characterized HCT. Our aim was to explore extent diversity ARD determine impact this on transplant outcome. Eight hundred ninety-one VUD-HCT donors...
These evidence-based guidelines expand and adapt previous guidance (Tomblyn et al, 2009; Andrews 2011). While specifically focusing on allogeneic haemopoietic stem cell transplantation (HSCT), they are relevant to other areas of haematological oncology where there is an increased risk cytomegalovirus (CMV) infection, such as cancers intense anti-T-cell therapy has been deployed (O'Brien 2006). The production these involved the following steps: CMV a herpes virus. Primary infection followed...
Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life-threatening complication that can develop after hematopoietic cell transplantation (HCT). While SOS/VOD may resolve within few weeks in the majority of patients with mild-to-moderate disease, most severe forms result multiorgan dysfunction and are associated high mortality rate (>80%). Therefore, careful surveillance allow early detection SOS/VOD, particularly licensed available drug proven...
The coronavirus disease 2019 (COVID-19) pandemic, a viral illness caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2),1 has produced at time of this writing nearly 33 million cases infection, with over deaths in 235 countries,2 causing an unprecedented burden on healthcare systems and global socioeconomic crisis. As pandemic spreads, knowledge course, as well potential risk factors predictors severity is increasing daily, initial data from randomised controlled studies...